In this episode of Hospital Medicine Unplugged, we blitz hyperviscosity syndrome (HVS)—recognize fast, de-sludge the blood, protect the brain/retina, fix the cause.

We open with the big picture: HVS = impaired microcirculation from thick blood, most often paraproteins (IgM/IgG/IgA), cellular overload (erythrocytosis/leukocytosis), or cryoproteins. Classic triad: mucosal bleeding, visual changes, neurologic symptoms—but treat the patient, not the viscosity number.

Do-firsts at the bedside: focused neuro/ocular exam, fundoscopy (dilated/tortuous veins, hemorrhages), bleeding check. Draw CBC + smear (rouleaux? blasts?), quantitative Igs, SPEP/IFE, serum viscosity/WBV, CMP/LDH/uric acid. Add cryoglobulins and hepatitis serologies if cold phenomena/vasculitis. In cyanotic CHD, pull iron studies.

When to act—now if symptoms:

Anesthesia/ICU pearls: avoid hypotension/dehydration that spikes viscosity; warm samples for cryoglobulins; don’t delay TPE for labs when the triad + fundus is screaming HVS.

Monitoring that matters: trend symptoms and fundus, not just numbers. Follow Ig levels, CBC/hematocrit, viscosity/WBV (selectively), renal/hepatic function, and iron status in cyanotic CHD. Watch for rebound after TPE if cytoreduction hasn’t started.

Complication radar: retinal hemorrhage/vision loss, CNS events, HF/pulmonary HTN, skin ischemia (cryoglobulins), therapy-related bleeding/infection/hypocalcemia. Older adults with myeloma + HVS carry higher early mortality—speed is therapy.

Etiology snapshots:

Medication/sequence pitfalls you don’t want to meet: treating numbers instead of symptoms, delaying TPE for confirmatory tests, rituximab IgM flare without TPE in symptomatic WM, routine phlebotomy in cyanotic CHD, and forgetting early chemo/targeted therapy after exchange.

We close with a ward-to-ICU bundle that sticks: (1) recognize the triad + fundus, (2) draw CBC/Ig/viscosity but start TPE/leukapheresis based on symptoms, (3) etiology-specific cytoreduction early to prevent rebound, (4) hydrate, warm, avoid hypotension, (5) tailor CHD care (iron repletion, sparing phlebotomy), (6) cryoglobulin protocol (warm handling, TPE + driver therapy), (7) daily vision/neuro checks + labs, (8) plan long-term disease control and secondary prevention.

Thick blood, thin margin—move fast, exchange early, and fix the source.

In this episode of Hospital Medicine Unplugged, we rapid-fire hip fracture care—spot it early, operate within 24–48 hours, mobilize fast, prevent complications, and lock in secondary prevention.

We open with the do-firsts: anterior groin pain, inability to bear weight, shortened/external rotation. Get AP pelvis + cross-table lateral; if films are normal but suspicion stays high, MRI (occult fracture catcher)—CT is reasonable if faster/available.

Triage & team: orthopedics + hospitalist/geriatric co-management from the ED. Stabilize meds/fluids/electrolytes, correct anemia, manage cardiac issues without needless delays. Multimodal analgesia (scheduled acetaminophen ± cautious NSAID, femoral/fascia-iliaca block) to cut opioids and reduce delirium.

Timing that saves lives: early surgery in 24–48 hours → fewer complications, shorter LOS, better function, lower mortality. Delay only for active, correctable instability (e.g., sepsis, decompensated HF).

Choose the operation by fracture type:

Peri-op safety bundle:

Post-op game plan—move early: WBAT for most; PT/OT day 1. Manage anemia (transfuse if symptomatic or Hb ≤8 g/dL), nutrition support, bowel regimen, and clear goals-of-care.

Secondary prevention (don’t miss the second hit):

Discharge & transitions: start planning on day 1. Match setting to function/support (inpatient rehab/SNF/home-with-therapy). Hand off weight-bearing status, wound/VTE plans, analgesia, bone meds, and red-flag symptoms. Arrange early outpatient follow-up.

Prognosis reality check: one-year mortality approaches 30% in older adults—driven by age, frailty, comorbidity, delays, and complications. The antidote is systematized care: fast diagnosis, early OR, multimodal analgesia with nerve blocks, VTE/pressure-injury/delirium prevention, early rehab, and osteoporosis treatment.

We close with the ward-ready bundle that sticks: (1) ECG/labs/films ± MRI when indicated; (2) analgesia pathway + nerve block; (3) OR in ≤48h unless actively unstable; (4) procedure matched to fracture; (5) VTE + antibiotic bundle; (6) day-1 mobilization with PT/OT; (7) osteoporosis + falls clinic on discharge. Fast, team-based, complication-light care—fix the fracture, protect the brain, and prevent the next one.

In this episode of Hospital Medicine Unplugged, we cut through DIC—systemic coagulation activation that causes microvascular thrombosis + consumptive bleeding—and show how to diagnose fast, treat the trigger, and tailor hemostatic support without fueling harm.

We open with the core phenotypes: SIC (sepsis) → early microthrombosis/organ dysfunction with modest bleeding; TIC (trauma) → early bleeding that later flips prothrombotic. Always anchor to context (sepsis, trauma, malignancy, obstetrics).

Recognition & labs you can’t skip:

Treatment—fix the cause, then the clotting:

ICU moves & monitoring that matter:

Pitfalls you’ll avoid:

We close with the system bundle: auto-trigger DIC/SIC scoring in sepsis/trauma, embed cause-first pathways (source control, hemostasis, oncology/OB), protocolized transfusion thresholds, VTE prophylaxis by platelet cutoffs, daily score-tracked rounds, and a hematology consult for thrombotic-dominant or refractory cases.

Treat the cause, individualize support, anticoagulate thoughtfully, and track the score—DIC management without the whiplash.

In this episode of Hospital Medicine Unplugged, we sprint through febrile neutropenia (FN)—antibiotics within 1 hour, risk-stratify smartly, de-escalate responsibly, and don’t miss invasive fungi.

We open with the do-firsts: rapid triage + focused exam (subtle signs count), two sets of blood cultures (peripheral + each central-line lumen), CBC with differential, renal/hepatic panels, early chest imaging if any respiratory hint, and targeted swabs/cultures per symptoms & season. Start empiric therapy before workup is complete.

Why FN is dangerous: risk climbs with ANC <500/µL (sky-high at <100/µL) and prolonged neutropenia—especially acute leukemia and post-transplant. Mucositis and central lines open the door; blunted inflammation hides trouble.

Empiric antibiotics—backbone moves (monotherapy preferred):

Risk-stratify to set the lane:

Stewardship that’s safe (and matters): in clinically stable, afebrile patients with no source and negative cultures, consider early de-escalation or discontinuation even before ANC recovery, per local policy—reduces exposure, resistance, and adverse events without harming outcomes.

If fever persists:

Therapeutic finesse: embrace therapeutic drug monitoring and individualized dosing (augmented renal clearance, third-spacing). Tailor to local antibiogram and prior colonization.

Duration—how to stop: if no pathogen, afebrile ≥24 h, negative cultures at 48 h, and clinically stable, stop or step down (especially low risk). If a source is found, treat per organism/site. High-risk patients often continue until count recovery—emerging data support earlier stop in carefully selected stable cases.

Adjuncts & support:

Common pitfalls you won’t make:

We close with the system plays: a “Golden Hour” FN bundle (STAT cultures → antipseudomonal β-lactam → fluids → imaging as indicated), built-in MASCC/CISNE scoring, outpatient pathway with daily follow-up and clear bounce-back rules, de-escalation timers, and an antifungal trigger at day 4–7.

Speed, spectrum, stratify, and steward—that’s how you bend FN outcomes in your favor.

In this episode of Hospital Medicine Unplugged, we blitz adrenal crisis—recognize fast, give hydrocortisone now, flood with isotonic saline, fix triggers, and keep it from coming back.

We open with the do-firsts: suspect crisis in any patient with known/suspected adrenal insufficiency who rolls in with hypotension/shock, abdominal pain, collapse, or altered mentation. Don’t wait for labs—this is a clinical diagnosis. Grab baseline tests while treating: Na/K/glucose/urea–creatinine, CBC, cortisol + ACTH (if it won’t delay therapy).

Call the pattern: hyponatremia, hyperkalemia (esp. primary AI), hypoglycemia (kids>adults), pre-renal azotemia. Infections, surgery, trauma, GI losses/vomiting, and steroid interruption are the usual triggers.

Treatment—hit the gas:

Risk & disposition: admit if shock, severe electrolyte derangements, infection, or unclear diagnosis; ICU for ongoing instability. Watch for refractory hypotension—hunt alternative/additional shock states.

Transition that sticks (once stable and taking PO):

Prevention plays—because recurrence hurts outcomes:

Controversies to watch:

Don’t-miss pearls & pitfalls:

We close with the system bundle: (1) auto-fire “adrenal crisis” order set (hydrocortisone + 0.9% saline + glucose); (2) bedside trigger checklist (infection, surgery, vomiting, med changes); (3) ICU handoff script for refractory shock; (4) discharge education + kit + written plan; (5) clinic follow-up to reinforce sick-day rules.

Recognize early, dose hydrocortisone immediately, resuscitate hard, treat the trigger, and hardwire prevention.

In this episode of Hospital Medicine Unplugged, we sprint through oncologic emergencies—recognize early, stabilize ABCs, start disease-directed therapy fast.

We sort the chaos into four bins: metabolic, hematologic, structural, and treatment-related. Across all bins: secure airway/breathing/circulation, get oncology on board, control symptoms, and loop in palliative care for values-aligned decisions.

Metabolic—act now:

Hematologic—time is tissue:

Structural—don’t miss the fixable:

Therapy-related—protocols save lives:

Triage cues for ICU/step-up: airway threat, shock, rapid neuro decline, refractory electrolyte derangements, rising lactate, or need for leukapheresis/plasmapheresis/dialysis.

Medication pitfalls to dodge:

We close with the Acute Oncology Bundle you can run today:

ABCs first + early ICU criteria.

Category check (metabolic/hematologic/structural/treatment-related).

Time-zero orders: labs (CBC, CMP, uric acid, LDH, coagulation), cultures if febrile, ECG, CXR.

Condition-specific therapy (e.g., rasburicase, bisphosphonate, antipseudomonal β-lactam, dexamethasone, stent, pericardiocentesis).

Oncology + subspecialists at the bedside (heme/onc, ICU, rad-onc, IR, neurosurg, cardio).

Palliative care early for goals, symptom control, and transitions when appropriate.

Daily re-risking and de-escalation/step-down plans.

Bottom line: recognize patterns, move fast, and match the fix to the physiology—that’s how you turn oncologic emergencies into stabilized patients and salvageable outcomes.

In this episode of Hospital Medicine Unplugged, we blitz superior vena cava syndrome (SVCS)—recognize fast, image smart, stent early, treat the cause.

We open with the do-firsts: airway and hemodynamic check, head-of-bed elevation, supplemental O₂, and lower-threshold ICU triage if stridor, confusion/syncope, hypotension. Contrast CT chest is your workhorse—maps level of obstruction, thrombus vs compression, collaterals, and guides the plan. MRV/US are add-ons when CT is contraindicated.

Name the culprit:

Supportive meds (use judiciously): dexamethasone (e.g., 4 mg q6h) may help in lymphoma/thymoma; diuretics sometimes used—but evidence is limited. Don’t let steroids delay tissue diagnosis in stable patients.

When to act now (emergencies): airway compromise, cerebral edema, hemodynamic instability → urgent endovascular stenting ± tumor-directed therapy.

Definitive management—build the plan around etiology and severity:

Antithrombotics after stent: practice varies; no consensus regimen—antiplatelet vs anticoagulation is individualized by thrombus burden, cancer, bleeding risk, and device factors. Document rationale.

Classify to triage: Use a simple clinical grading (e.g., Yale)—

Monitoring & follow-up that sticks: reassess symptoms 24–72h post-intervention; CT/venography at 1–3 months, then 6–12 months or sooner if relapse. Educate on red flags (worsening swelling, dyspnea, new neuro symptoms).

Complications—don’t miss: stent restenosis/thrombosis, migration, bleeding; disease-related pleural/pericardial effusions, thromboembolism. Have a low threshold for reintervention if symptoms recur.

Common pitfalls: delaying decompression in Grade III; starting steroids before biopsy in stable malignancy; over-relying on diuretics; skipping device evaluation/removal in thrombotic SVCS; failing to plan antithrombotics + surveillance.

We close with the SVCS bundle that works: (1) stabilize (airway/HOB/O₂), (2) contrast CT now, (3) biopsy before therapy if stable, (4) stent early for severe symptoms, (5) tumor-directed therapy for malignancy, (6) device management + anticoagulation for thrombotic cases, (7) structured antithrombotic plan post-stent (acknowledge uncertainty), (8) scheduled imaging follow-up and rapid reintervention pathway.

Bottom line: Image early, stent for speed, tailor therapy to cause, and plan antithrombotics + follow-up from day one.

In this episode of Hospital Medicine Unplugged, we face medical futility head-on—fair process over unilateral calls, structured communication over chaos, and ethics consultation as the engine that moves hard cases forward.

We start with the do-firsts: name the problem, clarify goals, and convene the team (primary, ICU, nursing, palliative, social work, chaplaincy). Square the facts with values: prognosis, likely outcomes, and what the patient would accept as a life worth living.

Call the concepts:

Procedural backbone (AMA CEJA):

Deliberation & resolution with all parties; seek common ground.

Secure alternatives if differences persist (second opinions, transfer).

Closure when alternatives are exhausted and the process is documented.

When to pull ethics in (don’t wait): overt conflict over life-sustaining treatment, requests judged nonbeneficial, unrepresented patients, or stalled goals-of-care talks. Many centers use mandatory consults for these triggers.

Use data, don’t be used by it: tools like GO-FAR (CPR outcomes) and the Clinical Frailty Scale inform CPR futility and discharge likelihood—supplement, never replace, clinical judgment and shared decision-making.

Communication that works (micro-playbook):

Ethical four-square—keep it visible: Autonomy, Beneficence, Non-maleficence, Justice. Use them to test options and explain recommendations.

Documentation essentials (make it audit-proof): clinical rationale for futility, details of every family meeting, participants, options discussed, ethics notes/recs, attempts to transfer, the final decision, and follow-up supports. If it isn’t documented, it didn’t happen.

Law & policy—quick compare:

What outcomes can you expect? Ethics consultation reduces nonbeneficial treatments, shortens ICU/hospital LOS, and improves decisional consensus; most clinicians and many families find it helpful—especially when they feel heard.

Common pitfalls to dodge: unilateral decisions, late ethics or palliative involvement, rigid numeric cutoffs, thin documentation, ignoring bias/disparities, and skipping data collection on policy use.

We close with the futility systems bundle you can deploy tomorrow:

Screen early for futility red flags (irreversible dependence, advanced metastatic disease, severe neuro injury, extreme frailty).

Default to structured conversations (SPIKES + VALUE) and time-limited trials when uncertainty remains.

Trigger ethics for conflict, unrepresented patients, or requests for nonbeneficial treatment.

Lean on data wisely (GO-FAR, CFS) to inform—not dictate—decisions.

Run the AMA process (deliberate → alternatives → closure) with meticulous documentation.

Embed palliative care and bereavement support.

Track outcomes (use of LST, LOS, satisfaction, disparities) to refine policy.

Bottom line: process over impulse, empathy over argument, clarity over confusion. Build a fair, transparent pathway that aligns treatment with patient values, minimizes harm, stewards resources, and supports families and clinicians when medicine cannot.

In this episode of Hospital Medicine Unplugged, we take on thrombotic thrombocytopenic purpura (TTP)—a hematologic sprint against time. Recognize fast, exchange plasma early, shut down antibody production, and stay ahead of relapse.

TTP is a life-threatening thrombotic microangiopathy marked by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia. Two types: immune-mediated (iTTP) from anti-ADAMTS13 autoantibodies, and congenital (cTTP) from inherited ADAMTS13 mutations. When ADAMTS13 activity plummets (<10%), ultra-large von Willebrand factor multimers accumulate, driving microvascular platelet-rich thrombi and organ injury.

Diagnosis is clinical—don’t wait for labs. Suspect TTP in any hospitalized patient with MAHA + thrombocytopenia and no alternative explanation. Classic pentad (anemia, thrombocytopenia, neuro findings, renal dysfunction, fever) is rare. Labs: CBC, peripheral smear (schistocytes ≥1%), LDH ↑, haptoglobin ↓, indirect bilirubin ↑, Coombs –, creatinine, and coag studies (typically normal). Send ADAMTS13, but start treatment immediately if TTP is suspected. Use PLASMIC ≥5 or FRENCH ≥1 scores to justify empiric therapy.

First-line therapy = plasma exchange (TPE) + corticosteroids.

Adjuncts that change the game:

Supportive care pearls:

Monitoring that matters:

Complications to anticipate:

Prognosis is vastly improved—with modern therapy, survival exceeds 90%. Relapse risk ~16% at five years, mitigated by early rituximab and vigilant ADAMTS13 monitoring.

Fast recognition, immediate plasma exchange, and smart immunomodulation save lives. In TTP, every hour counts—treat first, confirm later, and never underestimate the comeback.

In this episode of Hospital Medicine Unplugged, we blitz fungemia—treat early, pull the source, and outpace resistance (looking at you, Candida auris).

We open with the do-firsts: draw blood cultures (multiple sets) before therapy if you can, then start an echinocandin—caspofungin, micafungin, or anidulafungin—for most adults. They’re fungicidal, safe, and activity spans non-albicans. Layer rapid diagnostics (e.g., β-D-glucan, T2Candida where available) but don’t delay therapy.

Source control is non-negotiable: yank central venous catheters, drain abscesses, and audit devices/abdominal sites—delays mean higher mortality.

Initial therapy plays (adult, non-neutropenic):

Neutropenia & ICU: success rates mirror non-neutropenic patients; prefer non-polyene agents (echinocandins/azoles) for toxicity reasons. Voriconazole is reasonable if you need mold coverage.

C. auris essentials: start with an echinocandin first-line in adults and kids ≥2 months; azole resistance is common. Consider lipid amphotericin B if persistent fungemia or documented resistance. Step-down to an oral azole only with proven susceptibility. Expect higher recurrence; repeat cultures and re-check susceptibilities if breakthrough happens.

Empiric therapy sanity check (Sepsis Campaign): reserve empiric antifungals for real risk (neutropenia, multiple-site Candida colonization, recent abdominal surgery, persistent fever despite broad antibiotics). Routine empiric use doesn’t improve short-term mortality and inflates costs—be targeted.

Eyes & echo: everyone gets daily/every-other-day follow-up cultures until clearance. Dilated fundus exam within 1 week if following older practice; newer data/AAO suggest exam only with ocular symptoms—individualize. Use echo/abdominal imaging if endocarditis or deep foci suspected.

Step-down & tailoring:

Supportive care pearls: avoid platelet transfusions unless life-threatening bleeding; start VTE prophylaxis when platelets >50 × 10⁹/L; watch renal/hepatic labs and drug interactions (azole QT/CYPs, amphotericin nephrotoxicity).

Infection control (esp. C. auris): strict contact precautions, single rooms/cohorting, EPA List P disinfectants (chlorine/hydrogen peroxide); dedicated equipment and surveillance cultures during outbreaks. Public health notification early.

When the backbone buckles: persistent fungemia → confirm source control, re-sample, escalate/alter class (lipid AmB), and consult ID. Consider therapeutic drug monitoring for voriconazole.

Monitoring that sticks: trend platelets, creatinine, LFTs, and drug levels when indicated; repeat imaging if symptoms persist; ensure all criteria before stopping: culture clearance, symptom resolution, no deep focus, neutrophil recovery when relevant.

We close with the system moves—a fungemia bundle that: (1) pre-checks risk + cultures + BDG; (2) defaults to echinocandin first-line with weight/renal dosing; (3) auto-removes CVCs and hunts deep foci early; (4) runs daily/alt-day cultures to document clearance; (5) steps down only with susceptibility + stability; (6) flags C. auris for enhanced isolation + environmental disinfection; (7) embeds stewardship to avoid low-yield empiric use; (8) builds a discharge plan for duration, drug monitoring, and follow-up.

Fast recognition, early echinocandin, ruthless source control, and disciplined step-down—that’s how you turn fungemia from fatal to fixable.